

Vaccines of Covid-19


Shohael Mahmud Arafat¹, Kaushik Samanta², Tanuka Mandal³, Uddalak Chakraborty⁴

1 Professor, Department of Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka


2 Post graduate trainee, Department of General Medicine, R.G.Kar Medical College and Hospital

3 Senior Resident, Department of General Medicine, R.G.Kar Medical College and Hospital

4 Post graduate trainee, Department of General Medicine, R.G.Kar Medical College and Hospital



DNA plasmid vaccine with electroporation
Inovio Pharmaceuticals
 (Phase 1 NCT04336410)




RNA 3 LNP-mRNAs
BioNTech/Fosun Pharma/Pfizer
 (Phase 1/2 2020-001038-36)

RNA LNP encapsulated mRNA
Moderna/NIAID
 Phase 2 (IND submission) Phase 1 NCT04283461

NonReplicating Viral Vector
 Adenovirus Type 5 Vector
CanSino Biological Inc./Beijing Institute of Biotechnology
 (Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906)

NonReplicating Viral Vector ChAdOx1
University of Oxford
 (Phase 1/2 NCT04324606)



Vaccines in clinical evaluation

Platform	Type of candidate vaccine	Developer	Current stage of clinical evaluation
Non-Replicating Viral Vector	Adenovirus Type 5 Vector	CanSino Biological Inc./Beijing Institute of Biotechnology	Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906
RNA	LNP-encapsulated mRNA	Moderna/NIAID	Phase 2 (IND submission) Phase 1 NCT04283461
Inactivated	Inactivated	Wuhan Institute of Biological Products/Sinopharm	Phase 1/2 ChiCTR2000031809
Inactivated	Inactivated	Beijing Institute of Biological Products/Sinopharm	Phase 1/2 ChiCTR2000032459
Inactivated	Inactivated + alum	Sinovac	Phase 1/2 NCT04352608
Non-Replicating Viral Vector	ChAdOx1	University of Oxford	Phase 1/2 NCT04324606
RNA	3 LNP-mRNAs	BioNTech/Fosun Pharma/Pfizer	Phase 1/2 2020-001038-36
DNA	DNA plasmid vaccine with electroporation	Inovio Pharmaceuticals	Phase 1 NCT04336410